Kisspeptin-10 Dosage: The FDA’s Own 300-Subject Review
Kisspeptin-10 is the shortest active fragment of kisspeptin, the signal that switches on the reproductive hormone axis at puberty. It's genuinely one of the better human-dosed peptides on this site: FDA's own 2023 literature review counted roughly 300 human subjects across small IV, subcutaneous, and infusion studies. What it isn't is an approved treatment. That same FDA review recommended against adding it to the compounding bulks list, largely because approved testosterone therapies for secondary hypogonadism already exist and kisspeptin-10's own effectiveness data for that specific use is thin.
Reviewed by the PepGuard team · Last reviewed Jul 28, 2026
Synthetic 10-amino-acid C-terminal fragment of the KISS1 gene product (metastin): H-Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2 · also referred to as Metastin 45-54, KP-10
Photo: Adrian Sulyok / UnsplashA 2023 review that reads like a systematic literature search.
In 2023, a US compounding pharmacy asked the FDA to add kisspeptin-10 to the list of substances pharmacies can legally compound, specifically for “hormonal therapy to include treatment of male hypogonadism, preservation of spermatogenesis with testosterone therapies.” To evaluate that request, the FDA did something most vendor pages never do: it searched the published literature and counted every human subject who had actually been dosed with kisspeptin-10, then published its reasoning in a public briefing document.
That document is, in effect, a free systematic review, and it's the single best source on this page. It found roughly 300 human subjects dosed across small studies by IV bolus, subcutaneous bolus, and continuous infusion, in healthy volunteers, men and women with idiopathic hypogonadotropic hypogonadism, men with type 2 diabetes and low testosterone, women with hyperprolactinemia, and postmenopausal women. Then it recommended against compounding kisspeptin-10 anyway. The reasoning matters more than the verdict, see the regulatory section below.
What's actually been dosed, by whom.
| What's cited | Range |
|---|---|
| IV bolus range studied in humans (FDA's 2023 review of ~300 dosed subjects) | 0.01-13 mcg/kg; most common studied dose 0.31 mcg/kg |
| Subcutaneous bolus studied in humans (one trial, healthy women) | up to 42 mcg/kg, single dose |
| IV infusion studied in humans (postmenopausal women) | up to 12.5 mcg/kg/hour, for 24 hours |
| Commonly cited PCT/bodybuilding protocol (vendor/community, no trial behind this use) | 0.1-0.2 mg, subcutaneous, 2-3 times weekly |
| Human studies via intramuscular route | none identified, per FDA's own 2023 literature review, despite IM being one of the two routes proposed for compounding |
There's no single "Kisspeptin-10 dosage" the way most pages imply, because the human data comes from small mechanistic studies testing very different doses, routes, and populations, not a converged clinical protocol. The ranges below are what FDA's own 2023 review found when it surveyed the published human literature, not a recommendation. The vendor-cited PCT (post-cycle therapy) protocol is a separate, unvalidated convention with no trial behind it. Notably, FDA's review found zero human studies using the intramuscular route, despite IM being one of the two routes the 2023 compounding nomination proposed.
Kisspeptin-10 vs. kisspeptin-54: not the same trial data.
A widely covered 2023 randomized trial found that kisspeptin infusion improved sexual brain processing and penile tumescence in men with hypoactive sexual desire disorder, real, positive, peer-reviewed results. The peptide used in that trial was kisspeptin-54, the full-length, 54-amino-acid hormone, not kisspeptin-10, the 10-amino-acid fragment sold by research-peptide vendors and discussed everywhere else on this page.
Both fragments activate the same receptor (KISS1R), and both are described in the same body of reproductive-endocrinology literature, so this isn't a CB4211-style unrelated analog. But it's still a different molecule with its own trial, and that trial's libido and sexual-function results don't transfer to kisspeptin-10 by default just because the names look similar.
Fine acutely. Untested chronically.
| Signal | Frequency | Context |
|---|---|---|
| Flushing or injection site discomfort | commonly reported | Reported across several of the small acute-dosing human trials FDA reviewed; generally described as mild. |
| Acute safety signal in single or short-term dosing | rarely reported | FDA's own review of roughly 300 dosed subjects found no major safety concerns in acute IV or SC administration. |
| Effects of chronic or repeated dosing in men with reproductive disorders | unknown / not studied | FDA's 2023 review found no studies assessing adverse events for repeated dosing in the actual population, men being treated for secondary hypogonadism, that the compounding nomination targeted. |
| Effects via intramuscular administration | unknown / not studied | No identified human study has tested kisspeptin-10 given intramuscularly, despite IM being one of the two routes named in the 2023 nomination. |
| Immunogenicity from peptide-related impurities in compounded injectable formulations | unknown / not studied | FDA's stated concern: as a 10-amino-acid peptide given by injection, it "may pose a significant risk for immunogenicity," and neither the nomination nor the published literature ruled this out. |
Not FDA-approved. FDA's own 2023 review recommended against compounding inclusion; currently listed in 503A Category 2.
Kisspeptin-10 has never been approved by the FDA for any use. In 2023, a compounding pharmacy (Wells Pharmacy Network) nominated it for the FDA's 503A bulks list specifically for "hormonal therapy to include treatment of male hypogonadism, preservation of spermatogenesis with testosterone therapies," proposed as 1 mg/mL injectable solutions for subcutaneous or intramuscular use. FDA's resulting evaluation is unusually detailed and worth reading directly: the agency found kisspeptin-10 "not well characterized from the physical and chemical characterization perspective" because impurity and aggregate data were missing from both the nomination and the published literature, and concluded there was "a lack of information about whether kisspeptin-10 can be safely used in the intended population, the appropriate dose range, and frequency and duration of dosing." It also noted that "there are drug products approved by FDA that treat secondary hypogonadism in men" already, meaning kisspeptin-10 would be competing with, not filling a gap left by, existing approved therapies. Balancing these factors, FDA's evaluation "weighs against kisspeptin-10 being placed on the 503A Bulks List." It's currently listed under FDA's 503A Category 2 (bulk substances that raise significant safety risks), added September 29, 2023, over injectable-route immunogenicity concerns tied to its 10-amino-acid length and potential peptide-related impurities.
Every claim above, traced back.
Two primary human dosing trials, a comprehensive review, the kisspeptin-54 trial for comparison, and FDA's own 2023 briefing document and current compounding list. Click through and check them yourself.
Kisspeptin-10 questions, answered.
No. FDA reviewed it in 2023 after a compounding pharmacy nominated it specifically for treating male hypogonadism, and the agency's own evaluation recommended against adding it to the compounding bulks list, citing incomplete physicochemical characterization and a lack of effectiveness and long-term safety data for that exact use. It's currently listed under FDA's Category 2 (substances that raise significant safety risks).
More than most peptides on this site, yes. FDA's own literature review found roughly 300 human subjects dosed across small studies, IV boluses up to 13 mcg/kg, a subcutaneous study up to 42 mcg/kg in healthy women, and IV infusions up to 12.5 mcg/kg/hour in postmenopausal women, with no major acute safety concerns. What's missing is data on repeated or long-term dosing in the specific population, men with secondary hypogonadism, that most compounding demand is actually for.
Not exactly. The widely covered 2023 JAMA Network Open trial that found improved sexual brain processing and penile tumescence in men with hypoactive sexual desire disorder used kisspeptin-54, the full-length peptide, not kisspeptin-10, the shorter fragment sold by research-peptide vendors. Both activate the same receptor, but the specific trial data for that libido use applies to kisspeptin-54, not the molecule most vendors sell.
The rejection wasn't primarily about a safety event that occurred, it was about missing information and an existing alternative. FDA said it couldn't fully characterize the substance's impurity profile, found no studies on repeated dosing in the target population, found zero studies using the intramuscular route despite it being one of the two proposed, and noted that FDA-approved testosterone therapies for secondary hypogonadism already exist. That combination, not a specific adverse event, is what tipped the balance against inclusion.
Keep researching.
This is a preview of the Kisspeptin-10 report.
Create your account to check any peptide against the full research base.